1. Entering the Era of Clinical Proteomics: Utilizing Multiplexed Targeted Proteomics to Identify GC Patients Who May Benefit from Docetaxel: Reevaluation of the ITACA-S trial 
    January 2017, ASCOGI

  2. Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial 
    December 2016 - 17th World Conference on Lung Cancer

  3. Clinical mass spectrometry-based proteomics unlocks personalized medicine potential from bone metastases 
    December 2016 – EORTC-NCI-AACR
     
  4. Mass spectrometry-based proteomic analysis may improve identification of patients sensitive to FGFR inhibitor therapy 
    December 2016 – SABCS
     
  5. Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes 
    December 2016 – SABCS
     
  6. Identifying Patient-specific Neoepitopes for Cell-based and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes 
    November 2016, SITC
     
  7. Identifying Patient-specific Neoepitopes for Cell-based and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes 
    November 2016, EORTC
     
  8. Exploratory study of NQO1 expression in advanced solid tumors.  
    June 2016, ASMS
     
  9. Identifying Patient-specific Neoepitopes for Cell-based and Vaccine Immunotherapy Targets in Breast Cancer Patients by HLA Typing and Predicting MHC Presentation from Whole Genome and RNA Sequencing Data.
    June 2016, ASCO
     
  10. High-throughput Identification of Neoepitopes for Development of Patient-specific Cancer Immunotherapies 
    April 2016, AACR
     
  11. Quantitative HER2 protein expression analysis in multiple cancer indications: Identification of candidates for HER2 targeted therapies 
    March 2016, TAT
     
  12. KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma 
    January 2016, ASCO-GI
     
  13. Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial 
    December 2015, SABCS
     
  14. Integrating Whole Exome Sequencing Data with RNASeq And Quantitative Proteomics to Better Inform Clinical Treatment Decisions in Patients with Metastatic Triple Negative Breast Cancer 
    December 2015, SABCS
     
  15. Integrating Whole Genome Sequencing Data With RNAseq, Pathway Analysis, and Quantitative Proteomics to Determine Prognosis After Standard Adjuvant Treatment With Trastuzumab and Chemotherapy in Primary Breast Cancer Patients 
    December 2015, SABCS
     
  16. Whole genome sequencing and quantitative proteomics reveal HPV integration and HER2 overexpression in a patient with cervical cancer: Comprehensive omics analysis driving clinical treatment decisions 
    June 2015, AACR Precision Medicine Series
     
  17. Building patient-specific predictors of drug responses from cell line genomics 
    June 2015, AACR Precision Medicine Series
     
  18. Genomics, Transcriptomics, and Proteomics in the Clinical Setting: Integrating Whole Genome and RNA Sequencing With Quantitative Proteomics to Better Inform Clinical Treatment Selection 
    May 2015, ASCO
     
  19. HER2 Quantification By Targeted Proteomics Compared To IHC Or ISH In Predicting Clinical Benefit From Anti-HER2 Therapy In HER2-positive Breast Cancer 
    May 2015, ASCO
     
  20. Proteomic analysis of primary and metastatic breast cancers reveals a wide range of expression of the folate receptor, a potential drug target  
    May 2015, ASCO
     
  21. Quantitative measurement of HER2 levels by targeted proteomics predicts survival in gastric cancer patients treated with trastuzumab 
    May 2015, ASCO
     
  22. Diagnostic protein quantitation of actionable targets in patient biopsies using clinical mass spectrometry 
    May 2015, ASMS
     
  23. Her2 expression in gastroesophageal cancer (GEC) FFPE tissue using mass spectrometry (MS) and correlation with HER2 gene amplification 
    January 2015, ASCO-GI
     
  24. Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with anti-HER2 based therapy 
    December 2014, SABCS
     
  25. Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PD-L1 Protein in FFPE NSCLC Samples 
    November 2014, EORTC-NCI-AACR
     
  26. Quantification of ALK from Non-Small Cell Lung Cancer (NSCLC) FFPE Tissue by Targeted Mass Spectrometry 
    October 2014, Chicago Multidisciplinary Symposium in Thoracic Oncology
     
  27. High Levels of HER2 Measured By Multiplex Mass Spectrometry Correlate With Increased Overall Survival In Patients Treated With Anti-HER2 Therapy 
    May 2014, ASCO
     
  28. A comprehensive analysis of molecular profiles across over 10,000 tumor and germline exomes from over 5,000 patients across more than 20 tumor types 
    May 2014, ASCO
     
  29. Differential pathway activation associated with domain-specific PIK3CA mutations 
    April 2014, AACR
     
  30. Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PD-L1 Protein in FFPE NSCLC Samples 
    February 2014, IASLC
     
  31. Towards personalized treatment for gastroesophageal adenocarcinoma: Strategies to address inter- and intra- patient tumor heterogeneity: PANGEA 
    January 2014, ASCO-GI
     
  32. Quantification of MET Expression Using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue 
    January 2014, ASCO-GI
     
  33. Multiplexed Mass Spectrometry-based Assay to Quantify Translocation Markers from NSCLC FFPE Tissue 
    January 2014, AACR-IASLC
     
  34. Learning Regulatory Interactions with Paradigm 
    July 2013, ISBC
     
  35. Learning regulatory links in cancer through integrated pathway analysis with Paradigm 
    June, 2013
     
  36. Development of a Quantitative Gastroesophageal Cancer SRM assay for Use in FFPE Tumor Tissues 
    April 2013, AACR
     
  37. FOXM1 target genes associated with cell cycle regulation predict breast cancer metastatic outcome 
    April 2013, AACR
     
  38. Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS) 
    January 2013, ASCO-GI
     
  39. Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue 
    December 2012, SABCS
     
  40. Single-cell RNA sequencing of paclitaxel-treated breast cancer cell lines to find individual cell response 
    December 2012, SABCS
     
  41. Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multi-plex Assay for Use in FFPE Tissues 
    November 2012, EORTC-NCI-AACR
     
  42. Cancer genome sequencing analysis, storage, discovery and delivery 
    April 2012, AACR
     
  43. Integrated Genomic and Pathway Analysis Reveals Key Pathways across Breast Subtypes 
    December 2011, SABCS